{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"Lenalidomide 25 mg orally once daily for 21 days in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.\n\nDexamethasone 40 mg orally once daily on Days 1, 8, 15 and 22 in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.","id":"BG000","title":"Lenalidomide Plus Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.01","value":"74.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"≤ 75 Years Old"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"> 75 Years Old"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage III"}],"description":"The International Staging System (ISS) divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels.\n\nStage I: Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L);\n\nStage II: Neither stage I or III, meaning that either:\n\n* The beta-2 microglobulin level is between 3.5 and 5.5 (with any albumin level), OR\n* The albumin is below 3.5 while the beta-2 microglobulin is less than 3.5\n\nStage III: Serum beta-2 microglobulin is greater than 5.5.","paramType":"NUMBER","title":"Multiple Myeloma Stage before Study Entry","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"0 = Fully Active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"1= Restrictive but Ambulatory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"2 = Ambulatory but Unable to Work"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"3 = Limited Self-Care"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"4 = Completely Disabled"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}],"populationDescription":"The intent-to-treat (ITT) population consisted of all participants enrolled independent of whether they received study treatment or not."}